Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayvon Modjarrad

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
NPJ Vaccines|February 17, 2024
Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosetsIn-Jeong Kim, Olga Gonzalez, Michael P Tighe, et al.
Journal of Virology|October 27, 2021
Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus MacaquesJingyou Yu, Natalie D Collins, Noe B Mercado, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
Nature Communications|December 5, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccinesWei Chen, Kristin R Tompkins, Ian W Windsor, et al.
Nature Communications|July 29, 2015
Evaluation of candidate vaccine approaches for MERS-CoVLingshu Wang, Wei Shi, M Gordon Joyce, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 2, 2024
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national studyFaris G Bakri, Heyam H Mukattash, Hiam Esmeiran, et al.
The Journal of Infectious Diseases|May 11, 2022
Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019Shilpa Hakre, Ines Lakhal-Naouar, David B King, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
NPJ Vaccines|February 17, 2024
Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosetsIn-Jeong Kim, Olga Gonzalez, Michael P Tighe, et al.
Journal of Virology|October 27, 2021
Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus MacaquesJingyou Yu, Natalie D Collins, Noe B Mercado, et al.
The Lancet. Infectious Diseases|August 17, 2024
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trialKayvon Modjarrad, Paul T Scott, Melanie McCauley, et al.
Nature Communications|December 5, 2025
Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccinesWei Chen, Kristin R Tompkins, Ian W Windsor, et al.
Nature Communications|July 29, 2015
Evaluation of candidate vaccine approaches for MERS-CoVLingshu Wang, Wei Shi, M Gordon Joyce, et al.
NPJ Vaccines|March 19, 2023
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodiesShikha Shrivastava, Joshua M Carmen, Zhongyan Lu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 2, 2024
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national studyFaris G Bakri, Heyam H Mukattash, Hiam Esmeiran, et al.
The Journal of Infectious Diseases|May 11, 2022
Virological and Serological Assessment of US Army Trainees Isolated for Coronavirus Disease 2019Shilpa Hakre, Ines Lakhal-Naouar, David B King, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
The Lancet. Microbe|May 18, 2024
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trialBrittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
Pageof 14